Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Samsara, Thermo Fisher Scientific And More: CNBC's 'Final Trades'

Published 01/03/2024, 13:53
Updated 01/03/2024, 15:10
© Reuters.  Samsara, Thermo Fisher Scientific And More: CNBC's 'Final Trades'

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

On CNBC’s "Halftime Report Final Trades," Karen Firestone of Aureus Asset Management said Thermo Fisher Scientific Inc. (NYSE: TMO) is coming back from its covid lows.

On Feb. 21, Thermo Fisher Scientific raised its quarterly dividend from 35 cents to 39 cents per share. On Jan. 31, Thermo Fisher Scientific posted a fourth-quarter revenue of $10.89 billion, down 5% year-on-year (Y/Y), beating the consensus of $10.73 billion. Adjusted EPS was $5.67 versus the consensus of $5.64 and $5.40 a year ago, below the consensus of $5.42.

Shannon Saccocia of NB Private Wealth named the iShares U.S. Real Estate ETF (NYSE: IYR) as her final trade.

Don’t forget to check out our premarket coverage here

Josh Brown of Ritholtz Wealth Management said he likes Samsara Inc. (NYSE: IOT).

Samsara is expected to release its financial results for the fourth quarter of fiscal year 2024, which ended Feb. 3, 2024, after the closing bell on March 7, 2024. Analysts expect the company to report quarterly earnings at 3 cents per share, versus a year-ago loss of 2 cents per share. The company is projected to post quarterly revenue of $258.31 million, up from $186.58 million in the year-earlier period.

Price Action:

  • Thermo Fisher Scientific shares fell 0.3% to close at $570.18 on Thursday.
  • iShares U.S. Real Estate ETF rose 0.9% during Thursday’s session.
  • Samsara rose 4% to close at $34.55 on Thursday.

Photo: Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.